ReviewNature reviews. Gastroenterology & hepatology2020
Head-to-head trials in inflammatory bowel disease: past, present and future.
Review in Nature reviews. Gastroenterology & hepatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 33 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Prevalence of aphthous stomatitis in patients with inflammatory bowel disease after the treatment with monoclonal antibodies: a systematic review and meta-analysis.Medicina oral, patologia oral y cirugia bucal · 2022Pooled it
- Safety of S1P Modulators in Patients with Immune-Mediated Diseases: A Systematic Review and Meta-Analysis.Drug safety · 2021Pooled it
- c-Myc-PANK3-EMT axis regulates the structure and function of intestinal barrier in ulcerative colitis.Journal of advanced research · 2026Article
- Considerations in reviewing network meta-analyses of heterogeneous clinical trial designs: a methodological review in Crohn's disease and ulcerative colitis.Crohn's & colitis 360 · 2026Article
- Optimizing Drug Positioning in IBD: Clinical Predictors, Biomarkers, and Practical Approaches to Personalized Therapy.Biomedicines · 2026Review
- Dehydroandrographolide Alleviates Oxidative Stress, Inflammatory Response, and Pyroptosis in DSS-Induced Colitis Mice by Modulating Nrf2 Signaling Pathway.Biomolecules · 2025Article
- Gut microbiome in gastrointestinal neoplasms: from mechanisms to precision therapeutic strategies.Gut pathogens · 2025Review
- Coptis chinensis-derived extracellular vesicle-like nanoparticles delivered miRNA-5106 suppresses NETs by restoring zinc homeostasis to alleviate colitis.Journal of nanobiotechnology · 2025Article
- A Study of Patient Concerns in the Modern Therapeutic Era of Inflammatory Bowel Disease.Inflammatory bowel diseases · 2025Article
- Article
- Deciphering Microbial Composition in Patients with Inflammatory Bowel Disease: Implications for Therapeutic Response to Biologic Agents.Microorganisms · 2024Article
- Mendelian randomisation analysis for intestinal disease: achievement and future.eGastroenterology · 2024Review
- Pathogenesis and precision medicine for predicting response in inflammatory bowel disease: advances and future directions.eGastroenterology · 2024Review
- Chronic illness trajectory-based nursing intervention improves the self-care abilities of patients with inflammatory bowel disease.American journal of translational research · 2024Article
- Advancing therapeutic frontiers: a pipeline of novel drugs for luminal and perianal Crohn's disease management.Therapeutic advances in gastroenterology · 2024Review
- The Loss of YTHDC1 in Gut Macrophages Exacerbates Inflammatory Bowel Disease.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Efficacy and safety of adalimumab biosimilar (HS016) in inflammatory bowel disease from the real-world study.Frontiers in pharmacology · 2023Article
- Update on the role of upadacitinib in the treatment of adults with moderately to severely active ulcerative colitis.Therapeutic advances in gastroenterology · 2023Review
- Prediction and Verification of Potential Therapeutic Targets for Non-Responders to Infliximab in Ulcerative Colitis.Journal of inflammation research · 2023Article
- Epithelial NADFrontiers in immunology · 2023Article
Corrections and comments
- Erratum issued
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the increase in the number of novel drugs for inflammatory bowel disease (IBD), comparing therapeutic options or strategies has become a key challenge in IBD trials. Head-to-head trials designed and powered to enable formal comparisons are the gold standard in comparative research. Indeed, these trials are requested by some health authorities for evaluating the positioning of new treatments in IBD, as well as helping prescribing physicians to select the most appropriate treatment options for their patients. Despite head-to-head trials including aminosalicylate therapy in IBD having been performed decades ago, the first results of a randomized controlled trial directly comparing biologic agents with different modes of action have only now been published, mainly owing to important methodological issues. This Perspective provides an overview of the past, current and future concepts in IBD trial design, with a detailed focus on the role of comparative research and the challenges and pitfalls in undertaking and interpreting the results from such studies.
Indexed as
Identifiers
32303700What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.